-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The pharmaceutical arena is constantly surging.
According to related reports, since September 2021, more than 30 pharmaceutical companies from around the world have announced layoff plans
.
Among them, news about layoffs by pharmaceutical companies has been particularly frequent in the past month
.
It is reported that recently, a large vaccine company, Division K, has disclosed an urgent layoff plan: the compensation for leaving the company in the first half of April is N+1, and the compensation for leaving the company in the second half of the month is
N.
It is reported that the main reason behind this is that the company’s vaccine has not yet been launched and the production line has no product, so the decision to streamline product line expenditure and investment was made
.
On April 12, people familiar with the matter revealed that Novartis also plans to lay off thousands of jobs globally after it recently announced the integration of multiple business units to streamline the structure
.
Among them, more than 100 jobs could be lost at factories in Rothcruz and Basel, Switzerland
.
The company will use this initiative to improve efficiency and save costs
.
On April 10, it was reported that W Division, a major Internet medical company, is undergoing a round of major layoffs.
The number of employees has dropped from 4,000 in 2021 to 3,000, and there may be further reductions in the future
.
At the same time, there are also reforms of the compensation and welfare system, including reducing basic wages and linking employee compensation to performance
.
On March 28, 2022, Biogen announced that the clinical trial of BIIB078, an antisense nucleic acid drug for the treatment of amyotrophic lateral sclerosis (ALS), showed no clinical benefit, and decided to terminate the clinical trial
.
Then the media broke out that the company was implementing layoffs to cut costs
.
Judging from the motivation of major pharmaceutical companies to lay off staff, the main reason is not only affected by the epidemic, but also related to the pressure faced by the company
.
At present, the competition in the pharmaceutical market is fierce, and the medical reform policy continues to advance, forcing enterprises to speed up their transformation and upgrading.
At this time, enterprises generally cut costs, optimize the structure, and focus on advantageous businesses
.
In recent years, many pharmaceutical companies have adjusted their marketing strategies and development directions with changes in the market.
.
For example, increasing investment in research and development.
Judging from the financial data disclosed by major pharmaceutical companies recently, the research and development investment of many companies has increased significantly, and their technological innovation capabilities have been improved
.
For example, Clover's R&D expenditure from 2019 to 2020 increased from 45.
799 million yuan to 228 million yuan, a year-on-year increase of 398%
.
By 2021, Clover's R&D expenditure has reached 1.
826 billion yuan, a 7-fold increase from the same period last year; Hengrui Medicine's R&D investment in the first three quarters of 2021 has exceeded 4 billion yuan
.
After years of investment and accumulation, Hengrui's R&D innovation has ushered in a harvest period; Watson Bio's recently released investor relations activity record sheet shows that the company's R&D investment in 2021 will be 754 million yuan, of which R&D expenses will be 621 million yuan, reaching new highs in recent years
.
Under the continuous high investment in research and development, the company's research and development products have made great progress
.
There are also some companies speeding up the spin-off of non-core businesses and focusing on their main businesses.
For example, Pfizer spins off its patent expired drug and generic drug divisions Upjohn and merges with Mylan to form Viatris, and AstraZeneca spins off its China R&D center and China.
Invested in innovation and jointly established Dizal Pharma,
etc.
In general, with the changes in policies and markets, the development strategies of pharmaceutical companies cannot remain unchanged.
For pharmaceutical professionals, they need to continuously improve their professional capabilities and keep pace with the development of pharmaceutical companies in order to realize their own value.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
According to related reports, since September 2021, more than 30 pharmaceutical companies from around the world have announced layoff plans
.
Among them, news about layoffs by pharmaceutical companies has been particularly frequent in the past month
.
It is reported that recently, a large vaccine company, Division K, has disclosed an urgent layoff plan: the compensation for leaving the company in the first half of April is N+1, and the compensation for leaving the company in the second half of the month is
N.
It is reported that the main reason behind this is that the company’s vaccine has not yet been launched and the production line has no product, so the decision to streamline product line expenditure and investment was made
.
On April 12, people familiar with the matter revealed that Novartis also plans to lay off thousands of jobs globally after it recently announced the integration of multiple business units to streamline the structure
.
Among them, more than 100 jobs could be lost at factories in Rothcruz and Basel, Switzerland
.
The company will use this initiative to improve efficiency and save costs
.
On April 10, it was reported that W Division, a major Internet medical company, is undergoing a round of major layoffs.
The number of employees has dropped from 4,000 in 2021 to 3,000, and there may be further reductions in the future
.
At the same time, there are also reforms of the compensation and welfare system, including reducing basic wages and linking employee compensation to performance
.
On March 28, 2022, Biogen announced that the clinical trial of BIIB078, an antisense nucleic acid drug for the treatment of amyotrophic lateral sclerosis (ALS), showed no clinical benefit, and decided to terminate the clinical trial
.
Then the media broke out that the company was implementing layoffs to cut costs
.
Judging from the motivation of major pharmaceutical companies to lay off staff, the main reason is not only affected by the epidemic, but also related to the pressure faced by the company
.
At present, the competition in the pharmaceutical market is fierce, and the medical reform policy continues to advance, forcing enterprises to speed up their transformation and upgrading.
At this time, enterprises generally cut costs, optimize the structure, and focus on advantageous businesses
.
In recent years, many pharmaceutical companies have adjusted their marketing strategies and development directions with changes in the market.
.
For example, increasing investment in research and development.
Judging from the financial data disclosed by major pharmaceutical companies recently, the research and development investment of many companies has increased significantly, and their technological innovation capabilities have been improved
.
For example, Clover's R&D expenditure from 2019 to 2020 increased from 45.
799 million yuan to 228 million yuan, a year-on-year increase of 398%
.
By 2021, Clover's R&D expenditure has reached 1.
826 billion yuan, a 7-fold increase from the same period last year; Hengrui Medicine's R&D investment in the first three quarters of 2021 has exceeded 4 billion yuan
.
After years of investment and accumulation, Hengrui's R&D innovation has ushered in a harvest period; Watson Bio's recently released investor relations activity record sheet shows that the company's R&D investment in 2021 will be 754 million yuan, of which R&D expenses will be 621 million yuan, reaching new highs in recent years
.
Under the continuous high investment in research and development, the company's research and development products have made great progress
.
There are also some companies speeding up the spin-off of non-core businesses and focusing on their main businesses.
For example, Pfizer spins off its patent expired drug and generic drug divisions Upjohn and merges with Mylan to form Viatris, and AstraZeneca spins off its China R&D center and China.
Invested in innovation and jointly established Dizal Pharma,
etc.
In general, with the changes in policies and markets, the development strategies of pharmaceutical companies cannot remain unchanged.
For pharmaceutical professionals, they need to continuously improve their professional capabilities and keep pace with the development of pharmaceutical companies in order to realize their own value.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
